You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for MS 15203
MS 15203 is a potent and selective GPR171 partial agonist (EC50 = 90 nM; 28% inhibition of forskolin activated adenylyl cyclase activity in rat hypothalamic memebranes). Exhibits minimal binding to a panel of ~70 GPCRs and 10 other receptors (<22% of radioligand displaced from the target receptors). Increases neuronal activity in the paraventricular nucleus. Increases food intake and body weight in mice.
Compound Libraries for MS 15203
Technical Data for MS 15203
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for MS 15203
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for MS 15203
The following data is based on the product molecular weight 249.22. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.01 mL||20.06 mL||40.13 mL|
|5 mM||0.8 mL||4.01 mL||8.03 mL|
|10 mM||0.4 mL||2.01 mL||4.01 mL|
|50 mM||0.08 mL||0.4 mL||0.8 mL|
References for MS 15203
References are publications that support the biological activity of the product.
Wardman et al (2016) Identification of a small-molecule ligand that activates the neuropeptide receptor GPR171 and increases food intake Sci.Signal. 9 PMID: 27245612
If you know of a relevant reference for MS 15203, please let us know.
View Related Products by Product Action
Keywords: MS 15203, MS 15203 supplier, MS15203, GPR171, agonists, agonism, food, intake, body, weight, GPCR, neuropeptide, 6299, Tocris Bioscience
Citations for MS 15203
Citations are publications that use Tocris products.
Currently there are no citations for MS 15203. Do you know of a great paper that uses MS 15203 from Tocris? Please let us know.
Reviews for MS 15203
There are currently no reviews for this product. Be the first to review MS 15203 and earn rewards!
Have you used MS 15203?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Peptides Involved in Appetite Modulation Scientific Review
Written by Sonia Tucci, Lynsay Kobelis and Tim Kirkham, this review provides a synopsis of the increasing number of peptides that have been implicated in appetite regulation and energy homeostasis; putative roles of the major peptides are outlined and compounds available from Tocris are listed.
Stem Cells Scientific Review
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.